来自MSN28 天
Acrux scores fourth FDA approval, Nitroglycerin Ointment moving into commercialisation
Acrux Ltd (ASX:ACR) has been approved to begin U.S. commercialisation activities for its Nitroglycerin Ointment 0.4% targeting pain related to chronic anal fissures, with this marking the fourth ...
Medscape1 个月
Long-term results of topical glyceryl trinitrate ointment in children with anal fissure.
BACKGROUND/AIM: Although topical glyceryl trinitrate ointment (GTN) has become a popular treatment for anal fissure in adults, its use in children is still limited. We aimed to determine the ...
Nasdaq28 天
Acrux Limited Expands U.S. Market with New Ointment
Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Acrux Limited has commenced the commercial launch of its Nitroglycerin ... chronic anal fissure pain and taps ...